Vir Biotechnology, Inc.
Clinical trials sponsored by Vir Biotechnology, Inc., explained in plain language.
-
New drug combo aims to control Hard-to-Treat hepatitis d
Disease control OngoingThis phase 2 study tests two experimental drugs, VIR-2218 and VIR-3434, in about 95 adults with chronic hepatitis D. The goal is to see if the drugs can lower the virus level and improve liver health. Participants must have had hepatitis D for at least 6 months and be on certain …
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 17, 2026 02:43 UTC
-
New drug duo takes on stubborn hepatitis d in phase 2 trial
Disease control OngoingThis study tests whether a combination of two experimental drugs (Tobevibart and Elebsiran) works better than the current treatment Bulevirtide for people with chronic hepatitis D. About 100 adults with the virus will be followed for up to 240 weeks to see if the virus becomes un…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 17, 2026 02:42 UTC
-
New drug duo aims to control hard-to-treat hepatitis delta
Disease control OngoingThis phase 3 study tests whether a combination of two experimental drugs, tobevibart and elebsiran, can control chronic hepatitis delta virus (HDV) infection. About 124 adults with HDV will receive either the combo therapy right away or after a delay. The main goal is to see if t…
Phase: PHASE3 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC